MRK - Performance Comparison: Merck & Co And Competitors In Pharmaceuticals Industry | Benzinga
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Merck & Co (NYSE:MRK) against its key competitors in the Pharmaceuticals industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
Merck & Co Background
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Merck & Co Inc | |||||||
| 145.54 | |||||||
| 8.22 | |||||||
| 5.43 | |||||||
| 12.22% | |||||||
| $6.96 | |||||||
| $12.23 | |||||||
| 8.89% | |||||||
| Eli Lilly and Co | |||||||
| 115.34 | |||||||
| 58.10 | |||||||
| 19.69 | |||||||
| 19.02% | |||||||
| $3.12 | |||||||
| $7.09 | |||||||
| 25.98% | |||||||
| Novo Nordisk A/S | |||||||
| 45.83 | |||||||
| 41.10 | |||||||
| 16.75 | |||||||
| 24.73% | |||||||
| $36.91 | |||||||
| $55.43 | |||||||
| 22.45% | |||||||
| Johnson & Johnson | |||||||
| 22.48 | |||||||
| 5.20 | |||||||
| 4.44 | |||||||
| 4.69% | |||||||
| $5.68 | |||||||
| $14.87 | |||||||
| 2.34% | |||||||
| AstraZeneca PLC | |||||||
| 38.08 | |||||||
| 6.38 | |||||||
| 5.06 | |||||||
| 5.69% | |||||||
| $4.47 | |||||||
| $10.46 | |||||||
| 16.55% | |||||||
| Novartis AG | |||||||
| 23.37 | |||||||
| 5.29 | |||||||
| 4.47 | |||||||
| 6.23% | |||||||
| $4.66 | |||||||
| $9.02 | |||||||
| 9.71% | |||||||
| GSK PLC | |||||||
| 16.13 | |||||||
| 5.17 | |||||||
| 2.35 | |||||||
| 2.64% | |||||||
| $2.07 | |||||||
| $5.39 | |||||||
| 9.16% | |||||||
| Zoetis Inc | |||||||
| 33.60 | |||||||
| 15.73 | |||||||
| 9.20 | |||||||
| 11.91% | |||||||
| $0.93 | |||||||
| $1.55 | |||||||
| 9.5% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 45.35 | |||||||
| 0.89 | |||||||
| 1.53 | |||||||
| -0.04% | |||||||
| $186.41 | |||||||
| $668.37 | |||||||
| -5.43% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 17.14 | |||||||
| 3.38 | |||||||
| 3.42 | |||||||
| 4.76% | |||||||
| $20.32 | |||||||
| $49.91 | |||||||
| -1.83% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 22.49 | |||||||
| 1.85 | |||||||
| 1.96 | |||||||
| -0.39% | |||||||
| $0.23 | |||||||
| $0.81 | |||||||
| 1.03% | |||||||
| Prestige Consumer Healthcare Inc | |||||||
| 15.52 | |||||||
| 1.95 | |||||||
| 2.88 | |||||||
| 3.04% | |||||||
| $0.09 | |||||||
| $0.15 | |||||||
| -3.11% | |||||||
| Corcept Therapeutics Inc | |||||||
| 27.50 | |||||||
| 5.49 | |||||||
| 6.09 | |||||||
| 5.22% | |||||||
| $0.03 | |||||||
| $0.14 | |||||||
| 38.95% | |||||||
| Indivior PLC | |||||||
| 427.25 | |||||||
| 230.82 | |||||||
| 2.15 | |||||||
| 940.0% | |||||||
| $0.08 | |||||||
| $0.24 | |||||||
| 12.25% | |||||||
| Average | |||||||
| 65.39 | |||||||
| 29.33 | |||||||
| 6.15 | |||||||
| 79.04% | |||||||
| $20.38 | |||||||
| $63.34 | |||||||
| 10.58% |